Data / Drug companies / Carmustine
Carmustine: 13 companies and 14 products in the FDA NDC directory
Carmustine is listed in the FDA National Drug Code Directory by 13 companies, with 14 products in commercial distribution. 11 of the products (78.6%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are kit; wafer, and the newest product started marketing on October 1, 2025.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 13
- Products
- 14
- Generic (ANDA) products
- 11 (78.6%)
- Application numbers
- 10
- Routes
- Intravenous, Intracavitary
- Brand names
- Gliadel
- openFDA record search
- api.fda.gov
Companies that list carmustine
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Heritage Pharmaceuticals Inc. D/B/A Avet Pharmaceuticals Inc. | 2 | kit | Authorized generics (NDA) | March 1, 2021 |
| Alembic Pharmaceuticals Inc. | 1 | kit | Generic drugs (ANDA) | October 20, 2023 |
| Alembic Pharmaceuticals Limited | 1 | kit | Generic drugs (ANDA) | October 20, 2023 |
| Amneal Pharmaceuticals LLC | 1 | kit | Generic drugs (ANDA) | October 22, 2018 |
| Azurity Pharmaceuticals, Inc. | 1 | wafer | New drug applications (NDA) | December 13, 2012 |
| Dr. Reddy's Laboratories Inc. | 1 | kit | Generic drugs (ANDA) | October 4, 2021 |
| Dr. Reddy's Laboratories Inc. | 1 | kit | Generic drugs (ANDA) | October 1, 2025 |
| KVK-Tech, Inc. | 1 | kit | Generic drugs (ANDA) | March 1, 2024 |
| Meitheal Pharmaceuticals Inc. | 1 | kit | Generic drugs (ANDA) | August 2, 2021 |
| Navinta LLC | 1 | kit | Generic drugs (ANDA) | December 29, 2020 |
| Novadoz Pharmaceuticals LLC | 1 | kit | Generic drugs (ANDA) | May 11, 2023 |
| Sandoz Inc | 1 | kit | Generic drugs (ANDA) | May 26, 2021 |
| Zydus Pharmaceuticals USA Inc. | 1 | kit | Generic drugs (ANDA) | December 24, 2020 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Kit | 13 | 92.9% |
| Wafer | 1 | 7.1% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 11 | 78.6% |
| Authorized generics (NDA) | 2 | 14.3% |
| New drug applications (NDA) | 1 | 7.1% |
Pharmacologic classes
| Class | Products |
|---|---|
| Alkylating Drug | 1 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.